Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Special Survey of Production of Antibody Against Coagulation

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01586936

Enrollment

Registered

2012-04-27

Start date

1999-03-10

Completion date

2010-03-09

Last updated

2017-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

Brief summary

This study is conducted in Japan. The aim of this registry study is to observe the use of single dose and multi-dose use of eptacog alpha (NovoSeven®) and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.

Interventions

DRUGeptacog alfa (activated)

Prescription of eptacog alpha at the discretion of the physician

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Treated with eptacog alpha (NovoSeven®)

Exclusion criteria

* Investigator decision to measure for antibody as unnecessary medical testing

Design outcomes

Primary

Measure	Time frame
Antibody production against eptacog alpha	Up to 10 years

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026